HIF1A and Ewing sarcoma: Targeting the HIF-1α/miR-338-5p/IL-6 pathway may enhance CRC sensitivity to oxaliplatin, offering a novel therapeutic strategy against hypoxia-induced drug resistance.119 According to another study, in pediatric malignancies like rhabdomyosarcoma (RMS) and Ewing sarcoma (ES), HIF-1α mediates resistance to apoptosis under hypoxic settings.